• UK Clears New Bone Healing Device for NHS Use

    The UK cost containment agency, the National Institute of Health and Clinical Excellence (NICE), has issued final guidance recommending the use of Bioventus' innovative new bone healing device EXOGEN to treat long bone fractures that have failed to heal after 9 months. The device sends ultrasound waves to the fracture site and is intended for home use by the patient.  According to NICE's independent Medical Technologies Advisory Committee (MTAC), use of the ...
  • Novartis Cystic Fibrosis Drug Cleared for NHS Use

    The UK's cost containment agency, the National Institute of Health and Clinical Excellence (NICE), has issued a draft guidance recommending the use of Novartis' Tobi Podhaler, an inhaled tobramycin dry powder intended for the treatment of pseudomonas lung infections in persons with cystic fibrosis. NICE's recommendation comes as Forest Laboratories' competing drug Colobreathe (colistimethate sodium dry powder for inhalation) was not recommended for use by NICE because ...
  • Pfizer's Cyklokapron Green Lighted for Off-Label Use by NHS

    The UK's cost containment agency, the National Institute for health and Clinical Excellence (NICE), has published supporting evidence for the off-label use of Pfizer's Cyklokapron by the National Health Service (NHS) for significant severe bleeding following trauma.   The publication is the first edition of what NICE calls the Evidence Summary, which summarizes the published evidence for the off-label use of medicines for indications for which there are no...
  • Boehringer Ingelheim's Blot Clot Drug Cleared for NHS Use

    The UK's National Institutes of Health and Clinical Excellence (NICE), the country's cost containment agency, has cleared the use of Boehringer Ingelheim's alteplase (Actilyse) for the treatment of acute ischaemic stroke by the National Health Service (NHS) in  final guidance  issued on 26 September.   The guidance recommends starting treatment as early as possible within 4.5 hours after onset of stroke symptoms, and after intracranial haemorrhage has...
  • In Shakeup, UK Health Secretary Andrew Lansley Ousted

    • 04 September 2012
    UK National Health Secretary Andrew Lansley has been forced out of his position by Prime Minister David Cameron in the first major shakeup of the National Health Service (NHS) since Cameron took office in 2010, report numerous media outlets. In his stead will be new Health Secretary Jeremy Hunt, who was previously Secretary of Culture, Media and Sport. UK media outlets were quick to paint the decision as a controversial one, pointing out that Hunt was fighting to keep h...
  • NHS to be Called Out if NICE Guidance Not Followed

    • 30 August 2012
    The United Kingdom health minister said local National Health Service (NHS) organizations must provide a list of drugs approved by the National Institute for Clinical Excellence (NICE), according to a report in PMLive. Health minister Paul Burstow said the plan would get rid of drug blacklists and balance out pricing across the country. He said NHS would have no excuse not to provide the information with a new scorecard. "Patients have a right to drugs and treatments th...
  • New Electrosurgery Device Cleared for NHS Use

    The UK's National Institute of Health and Clinical Excellence (NICE), the country's health technology assessment agency, has cleared a new high tech monopolar electrosurgery device (Mega Soft Patient Return Electrode) for use by the National Health Service (NHS). The final guidance , issued on 22 August, advises that use of the device could help reduce the risk of localized burns during monopolar electrosurgery in select patients, such as those who would require shavin...
  • UK Convenes Expert Panel to Assess New Regulatory Framework for Implants

    • 15 August 2012
    The UK's Department of Health (DOH) is preparing to launch an expert inquiry into ways to protect consumers from potentially dangerous cosmetic implants, just months after UK regulators concluded there was significant room for improvement. In a 15 August press release , DOH said a panel of experts led by Sir Bruce Keogh, the National Health Service's medical director, would examine the regulatory framework for cosmetic products in the UK, the information available to pa...
  • UK NICE Gives Green Light to Servier's Procoralan for Chronic Heart Failure

    The UK's National Institute for Health and Clinical Excellence (NICE) on 7 August issued draft guidance recommending French drugmaker Servier Laboratories' cardiovascular drug Procoralan (ivabradine) be used by the National Health Service (NHS). In clinical trials, ivabradine has been shown to reduce mortality and improve quality of life in patients with certain forms of chronic heart failure. The draft guidance recommends ivabradine as an option for the treatment...
  • NICE Clears New Colposcopy Device for NHS Use

    DySIS Medical's colposcopy device for uterine examination has been cleared for use by the National Health Service in final guidance issued today by the the National Institute for Health and Clinical Effectiveness (NICE), the UK's health technology assessment body. The guidance is part of NICE's diagnostics assessment program, and it notes that a competing product, Imalux Corporation's Niris Imaging System, is not a "cost-effective option for the same indication." DyS...
  • UK: New Anti-clotting Drug Cleared for NHS Use

    According to final guidance issued 25 July by the National Institute of Health and Clinical Excellence (NICE) -- the UK's health technology assessment entity -- Bayer's Xarelto (rivaroxaban) has been cleared for use by the National Health Service (NHS) for treatment of deep vein thrombosis (DVT).   NICE officials said a key factor in the positive assessment was that the new oral anticoagulant is easier to use than warfarin because it does not require the...
  • NICE to Assume Review of High-cost Orphan Drug Products

    The UK's national health technology assessment (HTA) body, the National Institutes for Health and Clinical Excellence (NICE), is set to start assessing what it refers to as the "very high cost [of] drugs for people who suffer with rare conditions" under the new Health and Social Care Act of 2012. Under the plan, the agency-which assesses a product's value relative to its cost, societal impact and benefit to patients-would assume the responsibilities of conducting similar...